Navigation Links
Clarient to Present at the UBS 2007 Global Life Sciences Conference
Date:9/19/2007

ALISO VIEJO, Calif., Sept. 19 /PRNewswire-FirstCall/ -- Clarient, Inc. (Nasdaq: CLRT), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that it is scheduled to make an investor presentation at the UBS 2007 Global Life Sciences Conference at 4:30 p.m. EDT on Wednesday, September 26, 2007. The conference will be held at the Grand Hyatt in New York City, September 24-27.

A live webcast of the Company's presentation at the conference will be available via a link provided at http://www.clarientinc.com/investor. An archived replay of the presentation will be available shortly after the presentation is concluded for a period of 30 days.

About Clarient

Clarient combines innovative technologies with world class expertise to assess and characterize cancer. Clarient's mission is to provide the services, resources and critical information to improve the quality and reduce the cost of patient care as well as accelerating the drug development process. The Company's principal customers include pathologists, oncologists, hospitals and biopharmaceutical companies.

The rise of individualized medicine as the new direction in oncology has created the need for a centralized resource providing leading diagnostic technologies such as flow cytometry and molecular testing. Clarient is that resource, having created a state-of-the-art commercial cancer laboratory providing the most advanced oncology testing and drug development services available both onsite and over the web. Clarient is a Safeguard Scientifics, Inc. partner company. For more information, visit http://www.clarientinc.com.

About Safeguard

Safeguard Scientifics, Inc. (NYSE: SFE), a holding company, builds value in growth-stage technology and life sciences businesses. Safeguard provides growth capital as well as a range of strategic, operating and management resources to our partner companies. Safeguard participates in growth buyout financings, including corporate spin-outs and management buyouts, expansion financings, industry consolidations and early-stage financings. http://www.safeguard.com

Contact:

Matt Clawson John Baldissera

Allen & Caron, Inc. BPC Financial Marketing

(949) 474-4300 (800) 368-1217

matt@allencaron.com


'/>"/>
SOURCE Clarient, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Surgeons Presented Guidelines For Postoperative Atrial Fibrillation
2. Researchers Present Ways To Reduce The Risk Of Dementia
3. Researchers Present Data Regarding The Efficiency Of Herbs
4. Critically Ill Patients More At Risk Of Infection If Glucose Is Present In Their Lung Secretions
5. Ovarian Cancer Presents ‘Target Symptoms’ Six Months Before Diagnosi
6. Drug Reactions First Present Themselves In The Mouth
7. Reminiscing Into The Past Makes You Dissatisfied With The Present
8. Living In The Past Indicates Dissatisfaction With Present
9. Movies Represent Coma In A Wrong Way
10. Onchocerciasis: Presentation And Treatment
11. Researchers Warn That Routine Physical Examination Could Miss Breech Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... CT (PRWEB) , ... March 28, 2017 , ... ... devices, announces today that the University of Pittsburgh Medical Center (UPMC) will acquire ... and Western Pennsylvania. , The program, developed in association with efforts by the ...
(Date:3/28/2017)... ... March 28, 2017 , ... Calibration, qualification, and the ... results and maintaining GMP and USP compliance. In a new webinar from METTLER ... requirements " these requirements are explained. The challenge is to determine how ...
(Date:3/28/2017)... ... March 28, 2017 , ... With less than 10,000 dermatologists in the ... care can be limited while the desire to conquer breakouts and eliminate skincare stress ... for every customer online, today released its inaugural survey on the State of Acne ...
(Date:3/28/2017)... ... March 28, 2017 , ... Columbus OH. Dr. Justin Harper, Founder of Juvly ... professionals in the country to sit on the 2017 National Advisory Board for Allergan’s ... years Dr. Harper helped propel the clinic from a small start-up to number 78 ...
(Date:3/28/2017)... PA (PRWEB) , ... March 28, 2017 , ... Public ... and across a variety of business channels. , While many results are clear, ... any public relations program. , When it comes to measurement, firms should always ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... 2017  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a ... commercialization of innovative therapies for the treatment of ... Agency (EMA) has notified the company that the ... Application (MAA) has passed validation, and that the ... MAA for ARX-04 (known as DSUVIA™ in the ...
(Date:3/28/2017)... MARLBOROUGH, Mass. , March 28, 2017 /PRNewswire/ ... RNAi company developing innovative therapeutics that address significant ... granted a patent from the Japan Patent Office ... targeting connective tissue growth factor (CTGF) for the ... not limited to skin fibrosis and proliferative retinopathy ...
(Date:3/28/2017)... 28, 2017 The global ... 8.0 billion by 2025, according to a new study ... infectious diseases and cancer is expected to upsurge the ... over the coming years. In addition, higher number of ... allogenic stem cell therapy, due to adverse effects caused ...
Breaking Medicine Technology: